Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Toshner

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Statistical Methods in Medical Research|October 6, 2025
Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutionsRajenki Das, Nina Deliu, Mark R Toshner, et al.
Trials|July 11, 2025
StratosPHere 2: statistical analysis plan for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2Rajenki Das, Nina Deliu, Mark R Toshner, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2025
How Can We Ensure Accessible and High-Quality Specialist Care for Pulmonary Hypertension Patients?Jay Suntharalingam, Mark R Toshner, Kathy Blacker, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 3, 2013
Reply to "Letter to the editor: 'Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?'"Robert V Mackenzie Ross, Mark R Toshner, Elaine Soon, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 21, 2013
Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertensionRobert V MacKenzie Ross, Mark R Toshner, Elaine Soon, et al.
Thorax|March 13, 2016
The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunitiesFraser R Millar, Charlotte Summers, Mark J Griffiths, et al.
Cardiovascular Research|January 5, 2021
Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleusBenjamin J Dunmore, Rowena J Jones, Mark R Toshner, et al.
Human Molecular Genetics|May 15, 2013
The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutationsBenjamin J Dunmore, Kylie M Drake, Paul D Upton, et al.
High Altitude Medicine & Biology|January 1, 2009
NT-proBNP does not rise on acute ascent to high altitudeMark R Toshner, A A Roger Thompson, John B Irving, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 2, 2022
Prevalence and clinical significance of conduction disease in patients with idiopathic pulmonary arterial hypertensionSathineni Ashwin Reddy, Sarah L Nethercott, Wen Teh, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Statistical Methods in Medical Research|October 6, 2025
Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutionsRajenki Das, Nina Deliu, Mark R Toshner, et al.
Trials|July 11, 2025
StratosPHere 2: statistical analysis plan for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2Rajenki Das, Nina Deliu, Mark R Toshner, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2025
How Can We Ensure Accessible and High-Quality Specialist Care for Pulmonary Hypertension Patients?Jay Suntharalingam, Mark R Toshner, Kathy Blacker, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 3, 2013
Reply to "Letter to the editor: 'Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?'"Robert V Mackenzie Ross, Mark R Toshner, Elaine Soon, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 21, 2013
Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertensionRobert V MacKenzie Ross, Mark R Toshner, Elaine Soon, et al.
Thorax|March 13, 2016
The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunitiesFraser R Millar, Charlotte Summers, Mark J Griffiths, et al.
Cardiovascular Research|January 5, 2021
Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleusBenjamin J Dunmore, Rowena J Jones, Mark R Toshner, et al.
Human Molecular Genetics|May 15, 2013
The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutationsBenjamin J Dunmore, Kylie M Drake, Paul D Upton, et al.
High Altitude Medicine & Biology|January 1, 2009
NT-proBNP does not rise on acute ascent to high altitudeMark R Toshner, A A Roger Thompson, John B Irving, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 2, 2022
Prevalence and clinical significance of conduction disease in patients with idiopathic pulmonary arterial hypertensionSathineni Ashwin Reddy, Sarah L Nethercott, Wen Teh, et al.
Pageof 4